Plasma Level of Stromal Cell-Derived Factor-1 Provides Insight Into Statin Response, But Not Into Left Ventricular Dysfunction in New Unstable Angina

In patients with severe UA, plasma SDF-1 level showed significant variations with LDL-C levels and statin therapy suggesting that it can give insight into response to statin therapy regardless of LDL-C level. The ROC analysis showed favorable characteristics suggesting a potential usefulness of plasma SDF-1 assay to discriminate the statin-treated patients from those untreated. This novel approach highlights SDF-1 potential as a biomarker for monitoring statin therapy and predicting risks for adverse events in UA. Furthermore, it could pave the way for longitudinal studies with repeated measurements of plasma SDF-1 to evaluate its role as a prognostic indicator for major adverse cardiovascular events besides the other cardiovascular disease risk factors.